1. Home
  2. SLN vs CXDO Comparison

SLN vs CXDO Comparison

Compare SLN & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • CXDO
  • Stock Information
  • Founded
  • SLN 1994
  • CXDO 1995
  • Country
  • SLN United Kingdom
  • CXDO United States
  • Employees
  • SLN N/A
  • CXDO N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • CXDO Telecommunications Equipment
  • Sector
  • SLN Health Care
  • CXDO Telecommunications
  • Exchange
  • SLN Nasdaq
  • CXDO Nasdaq
  • Market Cap
  • SLN 165.3M
  • CXDO 169.5M
  • IPO Year
  • SLN N/A
  • CXDO 1998
  • Fundamental
  • Price
  • SLN $5.41
  • CXDO $5.45
  • Analyst Decision
  • SLN Buy
  • CXDO Strong Buy
  • Analyst Count
  • SLN 5
  • CXDO 2
  • Target Price
  • SLN $32.60
  • CXDO $8.75
  • AVG Volume (30 Days)
  • SLN 170.8K
  • CXDO 239.4K
  • Earning Date
  • SLN 05-08-2025
  • CXDO 05-06-2025
  • Dividend Yield
  • SLN N/A
  • CXDO N/A
  • EPS Growth
  • SLN N/A
  • CXDO 51.44
  • EPS
  • SLN N/A
  • CXDO 0.09
  • Revenue
  • SLN $27,701,000.00
  • CXDO $62,609,000.00
  • Revenue This Year
  • SLN N/A
  • CXDO $12.77
  • Revenue Next Year
  • SLN N/A
  • CXDO $11.09
  • P/E Ratio
  • SLN N/A
  • CXDO $61.26
  • Revenue Growth
  • SLN N/A
  • CXDO 13.85
  • 52 Week Low
  • SLN $1.97
  • CXDO $2.92
  • 52 Week High
  • SLN $22.47
  • CXDO $7.34
  • Technical
  • Relative Strength Index (RSI)
  • SLN 64.31
  • CXDO 50.98
  • Support Level
  • SLN $4.69
  • CXDO $5.08
  • Resistance Level
  • SLN $6.35
  • CXDO $5.79
  • Average True Range (ATR)
  • SLN 0.53
  • CXDO 0.29
  • MACD
  • SLN 0.08
  • CXDO -0.06
  • Stochastic Oscillator
  • SLN 62.25
  • CXDO 38.26

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.

Share on Social Networks: